handandwrist.co.in
Contracture

Dupuytren's Contracture

Progressive palmar fascia fibromatosis causing finger contractures. Also known as "Viking Disease". Complete guide to understanding, treatment options, and expected outcomes.

Understanding Dupuytren's Contracture

Dupuytren's contracture is a fibroproliferative disorder of the palmar fascia. The disease begins with nodules in the palm that progress to cords, eventually causing permanent flexion contractures of the fingers. The condition is painless but progressively limits hand function.

Epidemiology: Prevalence is highest in Northern European populations (9-22%), earning it the nickname "Viking disease." It affects men 7-10 times more frequently than women, with onset typically after age 40. Bilateral involvement occurs in 45-67% of cases.

Anatomy: The palmar fascia is a triangular sheet of connective tissue that helps grip. In Dupuytren's, myofibroblasts proliferate and produce excess collagen, forming nodules and cords that contract over time.

Risk Factors & Associations

Genetic & Demographics
  • • Northern European ancestry - strongest risk factor
  • • Family history - 68% heritability
  • • Male gender - 7-10x more common
  • • Age >40 years
  • • Bilateral disease - indicates aggressive diathesis
Medical Associations
  • • Diabetes mellitus - 5x increased risk
  • • Epilepsy/anticonvulsants
  • • Smoking - dose-dependent risk
  • • Alcohol excess
  • • HIV
  • • Manual labor - controversial

Dupuytren's Diathesis: Aggressive disease pattern characterized by: early onset (<50 years), bilateral involvement, family history, ectopic disease (Ledderhose - plantar, Peyronie's - penile, Garrod's - knuckle pads). These patients have higher recurrence rates after treatment.

Signs & Progression

Clinical Presentation

• Nodules: First sign - painless firm lumps in the palm

• Skin pitting: Dimpling of palmar skin

• Cords: Palpable bands extending from palm to fingers

• Contracture: Progressive finger flexion, cannot straighten

• Distribution: Ring finger (70%) > small finger (50%) > thumb (20%)

• Hueston tabletop test: Cannot place palm flat - indicates significant contracture

Early

Nodules only, no contracture

Mild

MCP contracture <30°

Moderate

MCP 30-60° or PIP involved

Severe

MCP >60° or PIP >30°

Diagnosis

Clinical Diagnosis: Dupuytren's is diagnosed clinically based on history and examination. Key findings:

  • Hueston Tabletop Test: Patient attempts to place palm flat on table. Inability to do so indicates significant contracture (usually >30° MCP or any PIP).
  • Palpation: Nodules and cords in palm and digits
  • Measure contracture: Document MCP and PIP angles with goniometer
  • Check for ectopic disease: Feet (Ledderhose), knuckle pads (Garrod's)

Imaging: Not typically required. Ultrasound can help differentiate from other soft tissue masses. MRI rarely needed.

Differential Diagnosis: Trigger finger (has catching), camptodactyly (congenital), post-traumatic contracture, Volkmann's contracture, dermatomyositis.

Treatment Options

Treatment Indications: Treatment is recommended when: MCP contracture exceeds 30°, any PIP contracture (>15-20°), or functional impairment. Early nodules without contracture are typically observed.

Needle Aponeurotomy (Percutaneous Needle Fasciotomy)

Office-based procedure using a needle to divide the Dupuytren's cord.

  • Best for: isolated MCP contractures with well-defined cord
  • Performed under local anesthesia
  • Immediate improvement
  • No incision, minimal recovery time
  • Recurrence rate: ~50% at 3-5 years
  • Risk: digital nerve injury (1-2%)
Collagenase Injection (Xiaflex)

Injectable enzyme (collagenase Clostridium histolyticum) that dissolves collagen in the cord.

  • Injection followed by manipulation 24-72 hours later
  • Best for single cord, MCP contracture
  • Less effective for PIP contractures
  • Recurrence rate: ~35-50% at 5 years
  • Side effects: bruising, swelling, skin tears
  • Risk: tendon rupture (rare)
Surgical Fasciectomy

Partial Fasciectomy: Surgical excision of diseased fascia. Gold standard treatment.

  • Best for: moderate-severe disease, multiple digits, PIP involvement
  • Lower recurrence than needle/enzyme (20-40% at 5-10 years)
  • Longer recovery (4-12 weeks)
  • Requires skilled hand surgeon

Dermofasciectomy: Removal of fascia AND overlying skin, replaced with skin graft.

  • Lowest recurrence rate
  • Reserved for: recurrent disease, severely involved skin
  • Longer recovery, skin graft donor site

Recovery & Rehabilitation

0-2 weeks
Early Phase
Wound care, extension splinting, gentle exercises. Hand therapy begins.
2-6 weeks
Progressive Phase
Increasing activity, night splinting continues, scar management, progressive grip strengthening.
6-12 weeks
Return to Activity
Full activities, splinting as needed (night splinting often continues 3-6 months).

Key Point: Night extension splinting is critical to maintain correction, especially for PIP contractures. Compliance with splinting significantly reduces recurrence risk.

Evidence & References

  • • Hurst LC, et al. Injectable collagenase Clostridium histolyticum for Dupuytren's contracture. NEJM. 2009
  • • Dias JJ, et al. Dupuytren's contracture: a systematic review. J Hand Surg Eur. 2017
  • • van Rijssen AL, et al. Five-year results of a randomized clinical trial on treatment in Dupuytren's disease: percutaneous needle fasciotomy versus limited fasciectomy. Plast Reconstr Surg. 2012
  • • Werker PM, et al. Dupuytren disease: FESSH guidelines. J Hand Surg Eur. 2018

Last Updated: January 2025 | Content reviewed by Dr. Deepthi Nandan Reddy, FRCS (Ortho)

Frequently Asked Questions

Consult Dr. Deepthi Nandan Reddy – Hand & Wrist Specialist

Get expert diagnosis and personalized treatment for your hand & wrist condition. Book your consultation today.

For appointments and complete profile, visit the main website